VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

IMW 2021 | Dasatinib plus nivolumab in patients with previously treated CML

Joaquin Martinez-Lopez, MD, PhD, of the Universidad Complutense de Madrid, Madrid, Spain, discusses a Phase I trial investigating the safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia (CML). Dr Martinez-Lopez reports that this combination has a favourable safety profile; however, the preliminary results showed low response rates. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.

Disclosures

Joaquin Martinez-Lopez, MD, PhD, has received grant support from BMS; and has performed consultancy work for BMS, Janssen, Novartis, GSK, Incyte, Roche and Astellas.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter